BIOPHYTIS (EPA:ALBPS) - Biophytis Trading will resume on February 14th, 2020 at 09:00 CET
Transparency directive : regulatory news
Click here to download pdf version
Biophytis Trading will resume on February 14th, 2020 at 09:00 CET
Paris (France), Cambridge (Massachusetts, U.S.), February 14, 2020, 08:00 CET -
Biophytis SA (Euronext Growth Paris: ALBPS - FR0012816825) announces that
trading will resume on February 14th, 2020 at 09:00 CET.
Following the stock price suspension from trading asked on February 13th before
the opening of the stock exchange and the company's press release of this
morning, trading will resume today at 09:00 CET.
Biophytis is a clinical-stage biotechnology company focused on developing
therapeutics that slow the degenerative processes associated with aging and
improve functional outcomes for patients suffering from age-related diseases,
with a primary focus on neuromuscular diseases.
Biophytis' lead drug candidate, Sarconeos (BIO101) is an orally administered
small molecule, which is currently in a Phase 2b clinical trial for sarcopenia
(SARA-INT) in the U.S. and Europe. A pediatric formulation of Sarconeos
(BIO101) is being developed for the treatment of Duchenne muscular dystrophy
(DMD), for which the company was granted FDA IND approval in December 2019.
Biophytis is headquartered in Paris, France, and has offices in Cambridge,
Massachusetts. The Company's ordinary shares are listed on Euronext Growth
Paris (Ticker: ALBPS - ISIN: FR0012816825).
For more information please visit www.biophytis.com
Biophytis Investor Relations Contact
Evelyne Nguyen, CFO
Europe Media Contact
Citigate Dewe Rogerson
Sylvie Berrebi / David Dible / Nathaniel Dahan / Quentin Dussart
Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571